Your browser doesn't support javascript.
loading
Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis.
Radocha, J; Hájek, R; Brozová, L; Pour, L; Spicka, I; Minarík, J; Gregora, E; Jungová, A; Jelínek, T; Heindorfer, A; Sýkora, M; Maisnar, V.
Afiliação
  • Radocha J; 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic. jakub.radocha@centrum.cz.
  • Hájek R; Czech Myeloma Group, Brno, Czech Republic. jakub.radocha@centrum.cz.
  • Brozová L; Czech Myeloma Group, Brno, Czech Republic.
  • Pour L; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
  • Spicka I; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Minarík J; Czech Myeloma Group, Brno, Czech Republic.
  • Gregora E; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine Masaryk Universtiy, University Hospital Brno, Brno, Czech Republic.
  • Jungová A; Czech Myeloma Group, Brno, Czech Republic.
  • Jelínek T; 1st Medical Department - Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
  • Heindorfer A; Czech Myeloma Group, Brno, Czech Republic.
  • Sýkora M; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic.
  • Maisnar V; Czech Myeloma Group, Brno, Czech Republic.
Ann Hematol ; 98(4): 951-962, 2019 Apr.
Article em En | MEDLINE | ID: mdl-30539278
ABSTRACT
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. The four major parameters with impact on survival were identified male gender, age > 75, creatinine > 152 µmol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p < 0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65 years.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Registros / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Registros / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article